Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.

Hum Vaccin Immunother · 2026 · PMC13387107 · PMID 42474387

Europe PMC DOI

hedged sentences

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

near-significantP = .096so close (0.05 < p ≤ 0.1)

The overall AEFIs reporting rate did not increase significantly after the adjustment (RR = 0.95, 95%CI : 0.83–1.08, P = .442), but notable dose-specific heterogeneity was observed: a near-significant increase for the first dose (RR = 1.67, P = .096), significant decreases for the second and third doses (RR = 0.70 and 0.40, respectively), and a substantially higher rate for the newly added fifth dose (684.84 per 100,000 doses).

also in 1,659 other papers

an increasing trendno p-value reported

The reporting rate of AEFIs following the first dose of DTaP showed an increasing trend in 2025, but this was not statistically significant (RR = 1.67, 95%CI : 0.91–3.07, P = .096).

also in 38,133 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.